

**MISSISSIPPI DIVISION OF MEDICAID
DRUG UTILIZATION REVIEW (DUR) BOARD
MINUTES OF THE JUNE 15, 2023 MEETING**

DUR Board Roster: State Fiscal Year 2023 (July 1, 2022 – June 30, 2023)	Sep 2022	Dec 2022	Mar 2023	Jun 2023
Joseph Austin, MD	✓	✓		✓
Lauren Bloodworth, PharmD				
Terrence Brown, PharmD	✓	✓	✓	✓
Patrick Bynum, MD	✓	✓		
Chrysanthia Davis, PharmD	✓	✓	✓	✓
Tanya Fitts, MD	✓			✓
Jahanzeb Khan, MD	✓	✓	✓	✓
Ray Montalvo, MD	✓		✓	
Holly Moore, PharmD	✓	✓	✓	✓
Kristi Phelps, RPh	✓	✓	✓	
Joshua Pierce, PharmD	✓	✓		✓
Bobbie West, MD	✓		✓	
TOTAL PRESENT**	11	8	7	7

*** Total Present may not be reflected by individual members marked as present above due to members who either resigned or whose terms expired being removed from the list.*

Also Present:

Division of Medicaid (DOM) Staff:

Terri Kirby, RPH, CPM, Pharmacy Director; Dennis Smith, RPH, DUR Coordinator; Gail McCorkle, RPH, Clinical Pharmacist; Chris Yount, MA, PMP-Office of Policy; Sue Reno, RN, Program Integrity; Vanessa Banks, RN, Program Integrity;

University of Mississippi School of Pharmacy - MS-DUR Staff:

Eric Pittman, PharmD, MS-DUR Project Director; Claire Lin, Graduate Student; Arman Arabshomali, Graduate Student; Alfred Eriakha, Graduate Student;

Change Healthcare Staff:

Paige Clayton, PharmD, On-Site Clinical Pharmacist; Shannon Hardwick, RPH, CPC Pharmacist;

Coordinated Care Organization (CCO) Staff:

Jenni Grantham, PharmD, Director of Pharmacy, Magnolia Health; Heather Odem, PharmD, Director of Pharmacy - Mississippi, UnitedHealthcare Community & State; Trina Stewart, PharmD, Pharmacy Manager, Molina Healthcare;

Gainwell Staff:

Tricia Banks, PharmD, MS Pharmacy Services Manager; Lew Ann Snow, RN, Advisor Business Analyst;

Alliant Health Staff:

Catherine Brett, MD, Quality Director, MS UM/QIO; Buddy Ogletree, PharmD, Pharmacist;

Visitors:

Cathy Prine-Eagle, Merck; Shawn Headley, Gilead; Michele Shirley, Indivior; Paula Whatley, Novo Nordisk; Keanna Dandridge, Novartis; Chandler Douglas, Capital Resources; Scott Roberson, Alkermes; Bridget Gipson, UCB; Jody Ray, SCA.

Call to Order/Welcome:

Dr. Brown called the meeting to order at 1:06 pm.

OLD BUSINESS:

Dr. Moore moved to approve the minutes from the December 2022 DUR Board Meeting, seconded by Dr. Pierce, and unanimously approved by the DUR Board.

Resource Utilization Review:

Dr. Pittman presented the resource utilization report for March 2023. Dr. Pittman noted that MS-DUR continues to experience data transfer issues with the encounter claims from Gainwell. DOM is working to resolve those issues.

NEW BUSINESS:

Update on MS-DUR Educational Interventions:

Dr. Pittman provided an overview of all DUR mailings and educational notices that occurred between February 2023 – May 2023. He also provided members with a proposed mailing on the preventive use of low-dose aspirin in pregnant beneficiaries at risk of preeclampsia. This mailing will be sent to over 3,400 providers that rendered pregnancy-related care to a Medicaid beneficiary during the previous year. The Board also recommended the educational mailing be distributed to pharmacists through pharmacy professional organizations.

Special Analysis Projects:

Adolescent Vaccines

Mississippi has traditionally performed well when it comes to childhood vaccination rates, particularly regarding vaccinations required for school attendance. With vaccinations that are not required for school attendance, Mississippi often lags behind other states. Efforts are ongoing to improve vaccination rates. This report examined trends in Tdap, meningococcal, and HPV vaccinations among Medicaid beneficiaries. Opportunities exist for the further advancement of vaccination rates in our state.

The following recommendation was presented:

1. DOM is encouraged to consider using this study as evidence to explore possible efforts or policy changes to promote increasing rates for the meningococcal, Tdap, and HPV vaccines.

Following discussion, Dr. Fitts made a motion to accept the recommendation, seconded by Dr. Pierce, and unanimously approved by the Board.

GLP-1 Trends

Dr. Pittman presented a report that examined healthcare utilization pre- and post-GLP-1 initiation for those beneficiaries initiated on a GLP-1 without the presence of a diabetes diagnosis in claims data. An interrupted time series study design was utilized to examine this impact. The ITS model demonstrated that the initiation of GLP-1s resulted in a significant increase in pharmacy and total healthcare costs immediately after initiation, but over the 12 months post initiation, pharmacy and total healthcare costs significantly decreased monthly. By the end of the 12-month post initiation period, a comparison of actual costs to the counterfactual estimates showed that although pharmacy costs were elevated, medical costs decreased resulting in a total healthcare cost that was only slightly higher than the counterfactual estimate. The Board also reviewed overall prescribing trends for GLP-1s between June 2022 and March 2023. A substantial increase in prescribing was noted across the entire class, including an increase in the number of non-preferred agents. Additionally, the Board had the opportunity to provide input on the proposed prior authorization criteria for select covered obesity medications set to go into effect July 1, 2023.

The following recommendations were presented:

1. DOM is encouraged to implement steps that promote the use of preferred GLP-1 agonists to combat the increase of prescribing of non-preferred agents.
2. DOM is encouraged to consider implementing a DUR+ (electronic PA) rule that promotes the utilization of GLP-1 agonists for appropriate diagnoses, based on FDA approval.
3. Due to the potential positive impact on medical and total healthcare costs, DOM is encouraged to consider allowing non-diabetic patients who are stable on preferred GLP-1 agents to continue therapy.

Following a robust discussion, Dr. Davis made a motion to accept the recommendations, seconded by Dr. Fitts, and unanimously approved by the Board.

FDA Drug Safety Updates:

Dr. Pittman updated the Board on FDA drug safety communications that were published between December 2022 – February 2023.

Pharmacy Program Update:

Ms. Kirby provided a pharmacy program update highlighting the following items:

- The names of new members to the Board have been submitted to the Governor’s Office. Ms. Kirby took the opportunity to commend all the current members that were completing their terms with the Board.
- DOM is in the midst of transitioning to multiple new vendors that provide pharmacy-related services.
- DOM is moving toward implementing a single PBA (pharmacy benefit administrator). This transition is set to take place July 2024.
- DOM submitted a waiver to CMS that will allow DOM to pay pharmacists for medication management services for members enrolled in the Elderly and Disabled Waiver Program beginning January 2024.

Next Meeting Information:

The next Board meeting is scheduled for September 7, 2023.

Dr. Brown adjourned the meeting at 2:49 pm

Submitted,

Eric Pittman, PharmD
Evidence-Based DUR Initiative, MS-DUR

Meeting Location: Woolfolk Building, 501 North West Street, Conference Room 145, Jackson, MS 39201, unless otherwise noted by the corresponding date of the meeting listed below.

Contact Information: Office of Pharmacy:

Chris Yount, 601-359-5253; Christopher.yount@medicaid.ms.gov, or
Jessica Tyson, 601-359-5253; jessica.tyson@medicaid.ms.gov

Notice details:

State Agency: MS Division of Medicaid

Public Body: Drug Utilization Board (DUR) Meeting

Subject: Quarterly Meeting

Dates and Times:

2023 dates:

- March 2, 2023 (1-3pm; Room 117, Woolfolk Building)
- June 15, 2023 (1-3pm; Room 145)
- September 7, 2023 (1-3pm; Room 145)
- December 7, 2023 (1-3pm; Room 145)

Description: The Mississippi Division of Medicaid's Drug Utilization Review (DUR) Board is a quality assurance body which seeks to assure appropriate drug therapy to include optimal beneficiary outcomes and appropriate education for physicians, pharmacists, and the beneficiary. The Drug Utilization Review (DUR) Board is composed of twelve participating physicians and pharmacists who are active MS Medicaid providers and in good standing with their representative organizations.

The Board reviews utilization of drug therapy and evaluates the long-term success of the treatments.

The Drug Utilization Review (DUR) Board meets quarterly.

Meetings


Meetings will be held at 1:00 pm in Woolfolk Building Room 145 unless otherwise noted. 2023 dates are as follows:

- ~~March 2, 2023 (Room 117, Woolfolk Building);~~
- June 15, 2023 (Room 145, Woolfolk Building);
- Sept. 7, 2023 (Room 145, Woolfolk Building),
- Dec. 7, 2023 (Room 145, Woolfolk Building)

All meetings will be live with no virtual options.

Important Updates: Beginning October 1, 2021, pharmaceutical and industry members, vendors, and general public must register to attend. Registration will open thirty (30) days prior to the meeting date. Registration will close at 12pm (noon) the day before the meeting. Public speaking is not allowed at DUR meetings unless called on by the Board.

Parking: parking may be found on the perimeter of the Woolfolk Building, on the north side of the Woolfolk Building located at the old Wright and Ferguson building (yellow/brown building), and at either the Division of Medicaid and First Baptist Church main parking lots at the corner of High Street and North President Street. *Guests may not park in the Woolfolk Building parking garage or in any parking space marked "Reserved".*

 **CLICK HERE to register online for the June 15, 2023 MS-DUR Board meeting!**

NOTE: Registration is **required** for all pharmaceutical industry and advocacy representatives to be able to attend DUR Board meetings.



NOTICE DETAILS

NOTICE DETAILS

State Agency: Division of Medicaid

Public Body: Division of Medicaid

Title: Division of Medicaid Drug Utilization Review Board Meeting

Subject: Division of Medicaid Drug Utilization Review Board Meeting

Date and Time: 6/15/2023 1:00:00 PM

Description:

Please see attached for more information regarding Drug Utilization Review Board Meeting. Meeting will take place in Room 145.

[Back](#)

MEETING LOCATION

501 N. West Street
Jackson MS 39201

[Map this!](#)

CONTACT INFORMATION

Chris Yount
6013595253
christopher.yount@Medicaid.ms.gov

DOWNLOAD ATTACHMENTS

Notification to DFA 2023 Pharmacy meetings -
DUR.docx
Added 1/25/2023

SUBSCRIPTION OPTIONS

Subscription options will send you alerts regarding
future notices posted by this public body.

[RSS](#)